Search

Your search keyword '"Baldari S."' showing total 165 results

Search Constraints

Start Over You searched for: Author "Baldari S." Remove constraint Author: "Baldari S." Search Limiters Available in Library Collection Remove constraint Search Limiters: Available in Library Collection
165 results on '"Baldari S."'

Search Results

2. 1394P Alkaline phosphatase (ALP) decline and pain response as markers for overall survival (OS) in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (223Ra) in the REASSURE study

3. State of the art of 18F-FDG PET/CT application in inflammation and infection: a guide for image acquisition and interpretation

4. Impact of COVID-19 on the imaging diagnosis of cardiac disease in Europe

5. Prevalence of interstitial pneumonia suggestive of COVID-19 at 18F-FDG PET/CT in oncological asymptomatic patients in a high prevalence country during pandemic period: a national multi-centric retrospective study

7. Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors

8. Impact of COVID-19 on the imaging diagnosis of cardiac disease in Europe

13. Impact of COVID-19 Pandemic on Cardiovascular Testing in Asia: The IAEA INCAPS-COVID Study

14. Impact of COVID-19 Pandemic on Cardiovascular Testing in Asia

15. Prevalence of interstitial pneumonia suggestive of COVID-19 at 18F-FDG PET/CT in oncological asymptomatic patients in a high prevalence country during pandemic period: a national multi-centric retrospective study

16. Regenerative medicine approaches for the management of respiratory tract fistulas

19. Recurrent bladder carcinoma: clinical and prognostic role of 18 F-FDG PET/CT

21. Correlation between histological grade and positron emission tomography parameters in cervical carcinoma

23. Italian Multicenter Study on Accuracy of 18 F-FDG PET/CT in Assessing Bone Marrow Involvement in Pediatric Hodgkin Lymphoma

24. Metabolic response assessment in non-small cell lung cancer patients after platinum-based therapy: A preliminary analysis

25. Evaluation of erlotinib treatment response in non-small cell lung cancer using metabolic and anatomic criteria

26. Use of bone health agents (BHAs) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) after abiraterone (Abi): An interim review of REASSURE

27. Tumour growth rate (TGR) when using lanreotide Autogel® (LAN) before, during and after peptide receptor radionuclide therapy (PRRT) in advanced neuroendocrine tumours (NETs)

29. Radium-223 with concomitant bone-targeting agents in metastatic castration-resistant prostate cancer (CRPC) patients treated in an international early access program (EAP)

30. Patient (pt) characteristics and treatment patterns in the radium (Ra)-223 REASSURE observational study

31. Changes in alkaline phosphatase (ALP) dynamics and overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients treated with radium-223 in an international early access program (EAP)

35. Evaluation of erlotinib treatment response in non-small cell lung cancer using metabolic and anatomic criteria

36. Analysis of overall survival by number of radium-223 injections received in an international expanded access program (iEAP)

38. 826P - Use of bone health agents (BHAs) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) after abiraterone (Abi): An interim review of REASSURE

39. 99mTc-MIBI SPECT in distinguishing neoplastic from nonneoplastic intracerebral hematoma

40. The relationship between cerebral vascular disease and parkinsonism: The VADO study

44. CKD LAB METHODS, PROGRESSION & RISK FACTORS 1

49. Retrospective analysis of the association of nodular goiter with primary and secondary hyperparathyroidism

Catalog

Books, media, physical & digital resources